Table Of Content

y3 ELSEVIER Author Index for Volume 20 ACTION II Study Investi- Drummond M, 479 Holloway RG, 369 gators, 493 Duggan C, 479 Huét C, 448 Age-Related Eye Disease Duhaylongsod F, 601 Hunsberger S, 52 Study Research Hunter DJ, 75 Group, 573 Eagle K, 297 Albert JM, 253 Eccles M, 479 Ioannidis JPA, 253 Antckli T, 601 Elbourne D, 149 Armitage P, 207, 229 Esposito R, 601 Jacob RG, 52 Exner DV, 319 Bailey G, 133 Kaufmann P, 52 Bain RP, 493 Fawzi WW, 75 Kepner JL, 353 Barbiere C, 601 Fergusson D, 448 Knottnerus JA, 386 Bauer P, 519 Feussner JR, 187 Korn EL, 395 Berger VW, 319 Fischer-Lapp K, 531 Krieger S, 133 Bielory L, 52 Fisher LD, 1, 16, 50 Krucoff M, 601 Birjiniuk V, 601 Floten H, 601 Krupski WC, 297 Black D, 121 Frankel MR, 369 Booth D, 601 Franzosi MG, 194 Lachin JM, 408 Borhani NO, 133 Frederick M, 52 Lai TL, 423 Borhani P, 133 Freedman BI, 493 Lakatos E, 121 Bozzette SA, 253 Freedman RR, 52 Langenberg M, 386 Breeson V, 133 Freemantle N, 479 Laupacis A, 448 Burack RC, 280 Freidlin B, 395 Lavori PW, 187 Burke GL, 267 LeBlanc M, 343 Garcia J, 149 Lemmens TG], 386 Carlin JB, 547 Gaus W, 511 Cartwright K, 493 Gehan EA, 555 Lesaffre E, 439 Cha SS, 242 Geller NL, 52 Levin J, 133 Chang MN, 353 George J, 280 Lewis D, 601 Littooy F, 297 Childhood Asthma Man- George SL, 395 agement Program Geraci B, 121 Liu PY, 343 Research Group, 91 Gifford DR, 369 Lodder J, 386 Clark HD, 448 Gimotty PA, 280 Lovato LC, 133 Concorde and Alpha Data Goetghebeur E, 531 Lucke JC, 601 and Safety Moni- Goldman S, 297 toring Committee, Grover F, 601 Mason J, 479 207 Gu M, 423 McAlister FA, 448 Cosgrove N, 133 McFalls EO, 297 Curcovic V, 601 Haines A, 479 McIntosh M, 253 Hanfelt JJ, 555 McNabb S, 297 Darbyshire J, 567 Hays MT, 187 Mooradian AD, 493 Davis B, 121 Heitjan DF, 309 Moritz T, 297 Delta Data and Safety Hellemons BSP, 386 Morrison DA, 601 Monitoring Com- Henderson W, 601 Moyé L, 40, 121 mittee, 229 Henderson WG, 297 Msamanga GI, 75 Desai M, 343 Hershon K, 493 Murphy E, 601 Diehr P, 267 Hill R, 52 Dippe S, 493 Hoffmeier M, 133 Nazareth I, 479 Dixon DO, 253 Hégel J, 511 Nicolis E, 194 Controlled Clinical Trials 20:620-621 (1999) © Elsevier Science Inc. 1999 655 Avenue of the Americas, New York, NY 10010 0197-2456/99/$-—see front matter 621 Author Index for Volume 20 Nyman JA, 297 Sethi G, 601 VA Cooperative Study SHEP Cooperative Study Program, AWE- Palmer CR, 172 Research Group, SOME Investiga- Patrick DL, 267 133 tors, 601 Petrovitch H, 133 Shuster JJ, 353 van Ree JW, 386 Pett S, 601 Slack RS, 555 Vermeer F, 386 Pledger G, 439 Sloan JA, 242 Vernon S, 601 Smith EA, 52 Vickrey BG, 369 Probstfield JL, 121, 133 Snowdon C, 149 Vogt T, 133 Spiegelman D, 75 Ramanathan KB, 601 Spinowitz BS, 493 Walley T, 479 Raya T, 601 Sugarman J, 187 Ward HB, 297 Robinson C, 601 Svolba G, 519 Weichung JS, 469 Rosenberger WF, 172, 328 Weiman D, 601 Russell I, 479 Talley JD, 601 Wells GA, 448 Thompson B, 52 Wigley FM, 52 Sacks J, 601 Tognoni G, 194 Williamson J, 267 Salmi LR, 448 Wilson AC, 133 Salsburg D, 453 Urassa EJN, 75 Wittes J, 121 Santoro E, 194 Wolfe R, 547 Sargent DJ, 242 VA Cooperative Study Wood J, 479 Schnittman SM, 253 Group on CARP Wuerth J-P, 493 Schouten HJA, 386 for Elective Vascu- Sedlis S, 601 lar Surgery, 297 Young P, 479 ELSEVIER Subject Index for Volume 20 ABSOLUTE RISK REDUCTION ALBUTEROL Comment on “The Number Needed to Childhood Asthma Management Treat,” 439 Program (CAMP): Design, Rationale, and Methods, 91 ACCRUAL Mass Mailing and Staff Experience in a ALLERGENS Total Recruitment Program for a Childhood Asthma Management Clinical Trial: the SHEP Program (CAMP): Design, Experience, 133 Rationale, and Methods, 91 ADAPTIVE DESIGN ALLOCATION CONCEALMENT Ethics and Practice: Alternative Designs Detecting Selection Bias in Randomized for Phase III Randomized Clinical Trials, 319 Clinical Trials, 172 Randomized Play-the-Winner Clinical ALPHA ALLOCATION Trials: Review and End-Point Interpretation in Clinical Recommendations, 328 Trials: The Case for Discipline, 40 ADVANCED GLYCOSYLATION ALZHEIMER’S DISEASE ENDPRODUCTS (AGEs) A Randomized Trial to Implement Design and Baseline Characteristics for Practice Recommendations: the Aminoguanidine Clinical Design and Methods of the Trial in Overt Type 2 Diabetic Dementia Care Study, 369 Nephropathy (ACTION II), 493 AMETHOCAINE AGE-RELATED MACULAR Sample-Size Calculation for a Log- DEGENERATION Transformed Outcome The Age-Related Eye Disease Study Measure, 547 (AREDS): Design Implications AREDS Report No.1, 573 AMINOGUANIDINE Design and Baseline Characteristics for AIDS TRIALS the Aminoguanidine Clinical Data and Safety Monitoring in the Trial in Overt Type 2 Diabetic Concorde and Alpha Trials, 207 Nephropathy (ACTION II), 493 Data and Safety Monitoring in the Delta Trial, 229 Rationale and Design of the Tanzania ANGINA Vitamin and HIV Infection A Multicenter, Randomized Trial of Trial, 75 Percutaneous Coronary Relationship Between Event Rates and Intervention Versus Bypass Treatment Effects in Clinical Site Surgery in High-Risk Unstable Differences Within Multicenter Angina Patients, 601 Trials:An Example from Primary Survival versus Years of Healthy Life: Pneumocystis carinii Prophylaxis, Which Is More Powerful as a 253 Study Outcome?, 267 Controlled Clinical Trials 20:622-631 (1999) © Elsevier Science Inc. 1999 655 Avenue of the Americas, New York, NY 10010 0197-2456 /99/$-see front matter Subject Index for Volume 20 623 ANOVA MODEL BREAKPOINT REGRESSION Comment on “Why Analysis of Variance Statistical Quality Control in Clinical is Inappropriate for Multiclinic Trials, 519 Trials,” 469 Why Analysis of Variance is BREAST CANCER Inappropriate for Multiclinic A Randomized Design of Repeated Trials, 453 Binary Outcomes Used to Evaluate Continued Effectiveness ANTICOAGULATION of a Breast Cancer Control Primary Prevention of Arterial Intervention Strategy, 280 Thromboembolism in Nonrheumatic Atrial Fibrillation: BRONCHODILATOR The PATAF Trial Study Design, Childhood Asthma Management 386 Program (CAMP): Design, Rationale, and Methods, 91 ANTI-INFLAMMATORY AGENTS Childhood Asthma Management BUDESONIDE Program (CAMP): Design, Childhood Asthma Management Rationale, and Methods, 91 Program (CAMP): Design, Rationale, and Methods, 91 ATRIAL FIBRILLATION Primary Prevention of Arterial CARDIOVASCULAR DISEASE Thromboembolism in Carvedilol and the FDA Approval Nonrheumatic Atrial Fibrillation: Process: The FDA Paradigm and The PATAF Trial Study Design, Reflections on Hypothesis 386 Testing, 16 Carvedilol and the Food and Drug BAYESIAN METHODS Administration Approval Data Monitoring Committees and Process: An Introduction, 1 Interim Monitoring Guidelines, Internet for Clinical Trials: Past, Present, 395 and Future, 194 Ethics and Practice: Alternative Designs A Multicenter, Randomized Trial of for Phase III Randomized Percutaneous Coronary Clinical Trials, 172 Intervention Versus Bypass Surgery in High-Risk Unstable BEHAVIORAL TREATMENT Angina Patients, 601 Behavioral and Pharmacologic Primary Prevention of Arterial Interventions: The Raynaud’s Thromboembolism in Treatment Study, 52 Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, BETA-CAROTENE 386 The Age-Related Eye Disease Study Prophylactic Coronary Artery (AREDS): Design Implications Revascularization for Elective AREDS Report No.1, 573 Vascular Surgery: Study Design, 297 BINARY OUTCOMES Survival versus Years of Healthy Life: False Positive Rates of Randomized Which Is More Powerful as a Phase II Designs, 343 Study Outcome?, 267 Worst-Rank Score Analysis with BLINDNESS Informatively Missing The Age-Related Eye Disease Study Observations in Clinical Trials, 408 (AREDS): Design Implications AREDS Report No.1, 573 CARVEDILOL Carvedilol and the FDA Approval BLOCKING Process: The FDA Paradigm and Detecting Selection Bias in Randomized Reflections on Hypothesis Clinical Trials, 319 Testing, 16 Subject Index for Volume 20 Carvedilol and the Food and Drug CUSUM CHARTS Administration Approval Statistical Quality Control in Clinical Process: An Introduction, 1 Trials, 519 Comment on “Carvedilol and the Food and Drug Administration DATA-DEPENDENT DESIGN Approval Process,” 50 Ethics and Practice: Alternative Designs End-Point Interpretation in Clinical for Phase III Randomized Trials: The Case for Discipline, 40 Clinical Trials, 172 CATARACT DEMENTIA The Age-Related Eye Disease Study A Randomized Trial to Implement (AREDS): Design Implications Practice Recommendations: AREDS Report No.1, 573 Design and Methods of the Dementia Care Study, 369 COMPLIANCE Practical Properties of Some Structural DESIGN PAPERS Mean Analyses of the Effect of The Age-Related Eye Disease Study Compliance in Randomized (AREDS): Design Implications Trials, 531 AREDS Report No.1, 573 Rationale and Design of the Tanzania Childhood Asthma Management Vitamin and HIV Infection Program (CAMP): Design, Trial, 75 Rationale, and Methods, 91 Design and Baseline Characteristics for CONGESTIVE HEART FAILURE the Aminoguanidine Clinical Carvedilol and the FDA Approval Trial in Overt Type 2 Diabetic Process: The FDA Paradigm and Nephropathy (ACTION II), 493 Reflections on Hypothesis A Multicenter, Randomized Trial of Testing, 16 Percutaneous Coronary Carvedilol and the Food and Drug Intervention Versus Bypass Administration Approval Surgery in High-Risk Unstable Process: An Introduction, 1 Angina Patients, 601 End-Point Interpretation in Clinical Primary Prevention of Arterial Trials: The Case for Discipline, 40 Thromboembolism in Worst-Rank Score Analysis with Nonrheumatic Atrial Fibrillation: Informatively Missing The PATAF Trial Study Design, Observations in Clinical Trials, 408 386 Prophylactic Coronary Artery Revascularization for Elective CORONARY BYPASS Vascular Surgery: Study Design, A Multicenter, Randomized Trial of 297 Percutaneous Coronary A Randomized Trial of Evidence-Based Intervention Versus Bypass Outreach (EBOR): Rationale and Surgery in High-Risk Unstable Design, 479 Angina Patients, 601 A Randomized Trial to Implement Practice Recommendations: CRITICAL RATIONALISM Design and Methods of the The Procedure of New Drug Application Dementia Care Study, 369 and the Philosophy of Critical Rationale and Design of the Tanzania Rationalism or The Limits of Vitamin and HIV Infection Quality Assurance with Good Trial, 75 Clinical Practice, 511 DIABETES MELLITUS CROSSOVER DESIGN Design and Baseline Characteristics for Ethics and Practice: Alternative Designs the Aminoguanidine Clinical for Phase III Randomized Trial in Overt Type 2 Diabetic Clinical Trials, 172 Nephropathy (ACTION II), 493 Subject Index for Volume 20 DOUBLE-PARALLEL DESIGN EPILEPSY Behavioral and Pharmacologic A Note on the Number Needed to Interventions: The Raynaud’s Treat, 439 Treatment Study, 52 EQUIPOISE DRUG INVESTIGATION Improving Informed Consent in Clinical The Procedure of New Drug Application Trials: A Duty to Experiment, 187 and the Philosophy of Critical A Note on Zelen Randomization: Rationalism or The Limits of Attitudes of Parents Participating Quality Assurance with Good in a Neonatal Clinical Trial Clinical Practice, 511 (letter), 569 DRUG LICENSING ESTIMATING EQUATIONS Commentary: Confirmatory Trials—A Practical Properties of Some Structural Mean Analyses of the Effect of New Approach?, 567 Compliance in Randomized The Procedure of New Drug Application Trials, 531 and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good ETHICS Clinical Practice, 511 Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172 ECMO TRIAL Improving Informed Consent in Clinical Ethics and Practice: Alternative Designs Trials: A Duty to Experiment, 187 for Phase III Randomized Randomized Play-the-Winner Clinical Clinical Trials, 328 Trials: Review and Randomized Play-the-Winner Clinical Recommendations, 328 Trials: Review and Zelen Randomization: Attitudes of Recommendations, 328 Parents Participating in a Neonatal Clinical Trial, 149 EDUCATIONAL OUTREACH A Randomized Trial of Evidence-Based EVENT RATES Outreach (EBOR): Rationale and Relationship Between Event Rates and Design, 479 Treatment Effects in Clinical Site Differences Within Multicenter ELDERLY Trials: An Example from Primary Mass Mailing and Staff Experience in a Pneumocystis carinii Prophylaxis, Total Recruitment Program for a 253 Clinical Trial: the SHEP Experience, 133 EXPERT OPINION Selecting Screening Criteria for Clinical Ethics and Practice: Alternative Designs Trials: An Example from the for Phase III Randomized Systolic Hypertension in the Clinical Trials, 172 Elderly Program, 121 Survival versus Years of Healthy Life: FALSE POSITIVE RATE Which Is More Powerful as a False Positive Rates of Randomized Study Outcome?, 267 Phase II Designs, 343 ENDPOINTS INTERPRETATION FDA DRUG APPROVAL End-Point Interpretation in Clinical Carvedilol and the FDA Approval Trials: The Case for Discipline, 40 Process: The FDA Paradigm and Reflections on Hypothesis ENVIRONMENTAL EXPOSURE Testing, 16 Childhood Asthma Management Carvedilol and the Food and Drug Program (CAMP): Design, Administration Approval Rationale, and Methods, 91 Process: An Introduction, 1 Subject Index for Volume 20 Comment on “Carvedilol and the FDA Treatment Effects in Clinical Site Approval Process,” 50 Differences Within Multicenter The Procedure of New Drug Application Trials: An Example from Primary and the Philosophy of Critical Pneumocystis carinii Prophylaxis, Rationalism or The Limits of 253 Quality Assurance with Good Clinical Practice, 511 HYPERTENSION Carvedilol and the Food and Drug FIXED UNEQUAL ALLOCATION Administration Approval Ethics and Practice: Alternative Designs Process: An Introduction, 1 for Phase III] Randomized Practical Properties of Some Structural Clinical Trials, 172 Mean Analyses of the Effect of Compliance in Randomized Trials, 531 FULLY SEQUENTIAL DESIGN Selecting Screening Criteria for Clinical Ethics and Practice: Alternative Designs Trials: An Example from the for Phase III Randomized Systolic Hypertension in the Clinical Trials, 172 Elderly Program, 121 GISSI INFORMED CONSENT Internet for Clinical Trials: Past, Present, Improving Informed Consent in Clinical and Future, 194 Trials: A Duty to Experiment, 187 Zelen Randomization: Attitudes of GLUCOCORTICOIDS Parents Participating in a Childhood Asthma Management Neonatal Clinical Trial, 149 Program (CAMP): Design, Rationale, and Methods, 91 INTENTION TO TREAT Causal Inference in a Clinical Trial: A GROUP-SEQUENTIAL TESTS Comparative Example, 309 Determination of Power and Sample Size Practical Properties of Some Structural in the Design of Clinical Trials Mean Analyses of the Effect of with Failure-Time Endpoints and Compliance in Randomized Interim Analyses, 423 Trials, 531 Group Sequential Trials for Phase II Trials with Historical Controls, 353 INTERIM ANALYSIS Data Monitoring Committees and HIERARCHICAL MODELS Interim Monitoring Guidelines, Relationship Between Event Rates and 395 Treatment Effects in Clinical Site Determination of Power and Sample Size Differences Within Multicenter in the Design of Clinical Trials Trials: An Example from Primary with Failure-Time Endpoints and Pneumocystis carinii Prophylaxis, Interim Analyses, 423 253 INTERNET HISTORICAL CONTROLS Internet for Clinical Trials: Past, Present, Group Sequential Trials for Phase II Trials and Future, 194 with Historical Controls, 353 INTERRATER AGREEMENT HIV INFECTION Assessing the Quality of Randomized Data and Safety Monitoring in the Trials: Reliability of the Jadad Concorde and Alpha Trials, 207 Scale, 448 Data and Safety Monitoring in the Delta Trial, 229 Rationale and Design of the Tanzania INTERVENTION STRATEGY Vitamin and HIV Infection Behavioral and Pharmacologic Trial, 75 Interventions: The Raynaud’s Relationship Between Event Rates and Treatment Study, 52 Subject Index for Volume 20 627 A Randomized Design of Repeated MONITORING Binary Outcomes Used to Commentary: Confirmatory Trials—A Evaluate Continued Effectiveness New Approach?, 567 of a Breast Cancer Control Data and Safety Monitoring in the Intervention Strategy, 280 Concorde and Alpha Trials, 207 Data and Safety Monitoring in the Delta JADAD SCALE Trial, 229 Assessing the Quality of Randomized Data Monitoring Committees and Trials: Reliability of the Jadad Interim Monitoring Guidelines, Scale, 448 395 Ethics and Practice: Alternative Designs for Phase III Randomized KIDNEY FAILURE Clinical Trials, 172 Design and Baseline Characteristics for Statistical Quality Control in Clinical the Aminoguanidine Clinical Trials, 519 Trial in Overt Type 2 Diabetic Nephropathy (ACTION II), 493 MONTE CARLO SIMULATIONS Determination of Power and Sample Size LIFE EXPECTANCY in the Design of Clinical Trials Survival versus Years of Healthy Life: with Failure-Time Endpoints and Which Is More Powerful as a Interim Analyses, 423 Study Outcome?, 267 MULTICENTER TRIALS MAILING LISTS Comment on “Why Analysis of Variance Mass Mailing and Staff Experience in a is Inappropriate for Multiclinic Total Recruitment Program for a Trials,” 469 Clinical Trial: the SHEP Mass Mailing and Staff Experience in a Experience, 133 Total Recruitment Program for a Clinical Trial: the SHEP MAMMOGRAPHY Experience, 133 A Randomized Design of Repeated Relationship Between Event Rates and Binary Outcomes Used to Treatment Effects in Clinical Site Evaluate Continued Effectiveness Differences Within Multicenter of a Breast Cancer Control Trials: An Example from Primary Intervention Strategy, 280 Pneumocystis carinii Prophylaxis, 253 MATCHED-PAIRS ANALYSIS Why Analysis of Variance is Sample-Size Calculation for a Log- Inappropriate for Multiclinic Transformed Outcome Trials, 453 Measure, 547 MULTIPLE SCLEROSIS META-ANALYSIS Causal Inference in a Clinical Trial: A Assessing the Quality of Randomized Comparative Example, 309 Trials: Reliability of the Jadad Scale, 448 MULTISTAGE DESIGN A Note on the Number Needed to A Modification of Simon’s Optimal Treat, 439 Design for Phase II Trials When Comment on “Why Analysis of Variance is Inappropriate for Multiclinic the Criterion is Median Sample Trials,” 469 Size, 555 Why Analysis of Variance is Sample Size and Design Considerations Inappropriate for Multiclinic for Phase II Clinical Trials with Trials, 453 Correlated Observations, 242 MISSING OBSERVATIONS NEONATAL TRIALS Worst-Rank Score Analysis with A Note on Zelen Randomization: Informatively Missing Attitudes of Parents Participating Observations in Clinical Trials, 408 in a Neonatal Clinical Trial Subject Index for Volume 20 (letter), 569 PEDIATRIC ASTHMA Zelen Randomization: Attitudes of Childhood Asthma Management Parents Participating in a Program (CAMP): Design, Neonatal Clinical Trial, 149 Rationale, and Methods, 91 PER-OBSERVATION ANALYSIS NONCOMPLIANCE Sample Size and Design Considerations Causal Inference in a Clinical Trial: A for Phase II Clinical Trials with Comparative Example, 309 Correlated Observations, 242 Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and PHARMACOLOGICAL TREATMENT Interim Analyses, 423 Behavioral and Pharmacologic Practical Properties of Some Structural Interventions: The Raynaud’s Mean Analyses of the Effect of Treatment Study, 52 Compliance in Randomized A Randomized Trial of Evidence-Based Trials, 531 Outreach (EBOR): Rationale and Design, 479 NONIGNORABLE MODEL PHASE II TRIALS Causal Inference in a Clinical Trial: A False Positive Rates of Randomized Comparative Example, 309 Phase II Designs, 343 Group Sequential Trials for Phase II Trials with Historical Controls, 353 NUMBER NEEDED TO TREAT A Modification of Simon’s Optimal A Note on the Number Needed to Design for Phase II Trials When Treat, 439 the Criterion is Median Sample Size, 555 NUTRITION Sample Size and Design Considerations Rationale and Design of the Tanzania for Phase II Clinical Trials with Vitamin and HIV Infection Correlated Observations, 242 Trial, 75 PHYSICIAN RESPONSIBILITY End-Point Interpretation in Clinical OUTCOME ASSESSMENT Trials: The Case for Discipline, 40 A Randomized Trial of Evidence-Based A Randomized Trial to Implement Outreach (EBOR): Rationale and Practice Recommendations: Design, 479 Design and Methods of the Dementia Care Study, 369 PAIN MEASUREMENT Sample-Size Calculation for a Log- PLAY-THE-WINNER DESIGN Transformed Outcome False Positive Rates of Randomized Measure, 547 Phase II Designs, 343 Randomized Play-the-Winner Clinical Trials: Review and PARENTAL PARTICIPATION Recommendations, 328 A Note on Zelen Randomization: Attitudes of Parents Participating PNEUMOCYSTIS CARINII in a Neonatal Clinical Trial Relationship Between Event Rates and (letter), 569 Treatment Effects in Clinical Site Zelen Randomization: Attitudes of Differences Within Multicenter Parents Participating in a Trials: An Example from Primary Neonatal Clinical Trial, 149 Pneumocystis carinii Prophylaxis, 253 PEARSON SKEW DISTRIBUTIONS Why Analysis of Variance is PRACTICE GUIDELINES Inappropriate for Multiclinic End-Point Interpretation in Clinical Trials, 453 Trials: The Case for Discipline, 40 Subject Index for Volume 20 A Randomized Trial of Evidence-Based RECRUITMENT Outreach (EBOR): Rationale and Childhood Asthma Management Design, 479 Program (CAMP): Design, A Randomized Trial to Implement Rationale, and Methods, 91 Practice Recommendations: Mass Mailing and Staff Experience in a Design and Methods of the Total Recruitment Program for a Dementia Care Study, 369 Clinical Trial: the SHEP Experience, 133 Rationale and Design of the Tanzania PREVENTION Vitamin and HIV Infection Primary Prevention of Arterial Trial, 75 Thromboembolism in Selecting Screening Criteria for Clinical Nonrheumatic Atrial Fibrillation: Trials: An Example from the The PATAF Trial Study Design, Systolic Hypertension in the 386 Elderly Program, 121 A Randomized Design of Repeated Binary Outcomes Used to Evaluate Continued Effectiveness RECURSIVE RESIDUALS of a Breast Cancer Control Statistical Quality Control in Clinical Intervention Strategy, 280 Trials, 519 PSYCHOLOGICAL TESTING REGRESSIVE LOGISTIC ANALYSIS Analytical Implications of Changing A Randomized Design of Repeated Neuropsychological Test Binary Outcomes Used to Versions During a Longitudinal Evaluate Continued Effectiveness Study Because of Aging in a of a Breast Cancer Control Intervention Strategy, 280 Pediatric Cohort (letter), 476 RESEARCH PARTICIPATION QUALITY OF CARE Improving Informed Consent in Clinical A Randomized Trial to Implement Trials: A Duty to Experiment, 187 Practice Recommendations: Design and Methods of the Dementia Care Study, 369 RESTRICTED TESTS Why Analysis of Variance is QUALITY OF TRIALS Inappropriate for Multiclinic Assessing the Quality of Randomized Trials, 453 Trials: Reliability of the Jadad Scale, 448 REVASCULARIZATION Commentary: Confirmatory Trials—A A Multicenter, Randomized Trial of New Approach?, 567 Percutaneous Coronary The Procedure of New Drug Application Intervention Versus Bypass and the Philosophy of Critical Surgery in High-Risk Unstable Rationalism or The Limits of Angina Patients, 601 Quality Assurance with Good Clinical Practice, 511 RISK FACTORS Statistical Quality Control in Clinical A Note on the Number Needed to Trials, 519 Treat, 439 RANK ANALYSIS RUBIN CAUSAL MODEL Worst-Rank Score Analysis with Causal Inference in a Clinical Trial: A Informatively Missing Comparative Example, 309 Observations in Clinical Trials, 408 SAMPLE SIZE RAYNAUD'S DISEASE Determination of Power and Sample Size Behavioral and Pharmacologic in the Design of Clinical Trials Interventions: The Raynaud’s with Failure-Time Endpoints and Treatment Study, 52 Interim Analyses, 423